Company Overview
Quantum BioPharma Ltd. operates as a biopharmaceutical entity focused on researching and developing a portfolio of assets and biotech solutions designed for the treatment of neurodegenerative conditions. The company functions within the broader Healthcare sector and specifically within the Biotechnology industry, a classification that typically implies significant reliance on research and development cycles rather than immediate product revenue generation. In terms of scale, the company holds a market capitalization of $20.31M, though its annual revenue is not available for disclosure, and the employee count is listed as N/A. The valuation metric of $20.31M suggests a small-cap profile, indicating that the company operates with limited resources compared to large-cap peers and likely faces higher risk profiles associated with early-stage biotech development where revenue streams are often not yet established or are significantly below market expectations.
Financial Health
The company reports a net income of $-26,175,286 and an EBITDA of $-14,756,594, while revenue data is unavailable for the trailing twelve months. The substantial gap between the reported net income and EBITDA reveals a significant cost structure burden, specifically indicating that interest expenses, taxes, or amortization of intangible assets are consuming a large portion of the operating earnings, resulting in a net loss that exceeds the EBITDA loss. Free cash flow stands at $-7,390,729, which indicates that the company is currently burning cash through its operations and investing activities, thereby limiting its immediate financial flexibility without external capital injections. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that technically denotes a lack of profitability on a percentage basis and suggests that current revenue, if any, is being entirely consumed by costs or that no revenue data is being reported in the standard format. The company holds $2.36M in cash against $1.88M in debt, resulting in a debt-to-equity ratio of 36.77; this leverage level is moderate but must be viewed cautiously given the negative cash flow and lack of positive earnings to service that debt. The current ratio is 1.07, which indicates that the company possesses slightly more current assets than current liabilities, suggesting a fragile but technically solvent short-term liquidity position. Furthermore, the return on equity is -346.9% and the return on assets is -67.6%, metrics that reveal management is currently generating significant value destruction relative to the capital invested in the company.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed as -0.61, a negative figure that implies the market expects continued negative earnings in the near term. The price-to-book ratio is 2.64, which indicates that the market is currently pricing the company at a premium of 164% over its net asset book value, a valuation characteristic often found in biotech firms where future potential assets are valued higher than their current tangible worth. The price-to-sales ratio is N/A, and the EV/EBITDA is -1.08, suggesting that alternative valuation multiples are also skewed negative due to the company's financial losses and lack of established sales figures. The stock has a 52-week high of $38.25 and a 52-week low of $2.07, placing the current trading price significantly below the recent peak but well above the floor, reflecting high volatility common in small-cap biotechnology stocks. The beta is N/A, meaning volatility relative to the broader market cannot be quantified from the provided data, but the wide range between the high and low suggests extreme price sensitivity to market sentiment and sector-specific news.
Growth & Income
Revenue growth and earnings growth year-over-year are both N/A, reflecting the fact that the company does not yet have a consistent historical record of positive growth metrics to analyze. Consequently, there is no data to determine if earnings are growing faster or slower than revenue, as the fundamental growth trajectory remains undefined by historical performance. As the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders and instead retains all earnings, which are currently negative, for reinvestment into research and development. The overall growth and income profile is characterized by a complete absence of historical growth rates and dividend income, relying entirely on future clinical trial successes to potentially alter this trajectory.